Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 3/20 | 0.37 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.37 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.33 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | ATR | Q13535 | 2/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | F2R | P25116 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30388040 | 1.00 | CYP4F2 (0.37) | CYP4F2CYP4A11RETDGAT2FGFR1 | |
| SCHEMBL4905180 | 1.00 | CYP4F2 (0.37) | CYP4F2CYP4A11RETDGAT2FGFR1 | |
| SCHEMBL30236077 | 1.00 | CYP4F2 (0.37) | CYP4F2CYP4A11RETDGAT2FGFR1 | |
| SCHEMBL32682437 | 0.88 | RET (0.33) | CYP4F2CYP4A11RETDGAT2FGFR1 | |
| SCHEMBL4053570 | 0.88 | RET (0.37) | CYP4F2CYP4A11RETDGAT2FGFR1 | |
| SCHEMBL4053575 | 0.88 | RET (0.37) | CYP4F2CYP4A11RETDGAT2FGFR1 | |
| SCHEMBL29705188 | 0.87 | FGFR1 (0.38) | CYP4F2CYP4A11RETFGFR1MEN1 | |
| SCHEMBL18198891 | 0.87 | FGFR1 (0.38) | CYP4F2CYP4A11RETFGFR1MEN1 | |
| SCHEMBL3715963 | 0.87 | IP6K1 (0.33) | CYP4F2CYP4A11RETDGAT2FGFR1 | |
| SCHEMBL3715961 | 0.87 | IP6K1 (0.33) | CYP4F2CYP4A11RETDGAT2FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112442009-A | Deuterated compounds and their use for treating cancer | 润佳（苏州）医药科技有限公司 | 2021-03-05 | — | — | CN | claimed |
| US-12162876-B2 | Indazole kinase inhibitor and use thereof | Tarapeutics Science Inc. (CN) | 2024-12-10 | — | — | US | disclosed |
| CN-112442009-B | Deuterated compounds and their use for treating cancer | 润佳（苏州）医药科技有限公司 | 2023-10-03 | — | — | CN | disclosed |
| CN-113350347-B | Use of indazoles | 安徽中科拓苒药物科学研究有限公司 | 2023-07-04 | — | — | CN | disclosed |
| CN-115974858-A | Acoxitinib impurity and preparation method thereof | 山东新时代药业有限公司 | 2023-04-18 | — | — | CN | disclosed |
| CN-111138426-B | Indazole kinase inhibitor and application thereof | 安徽中科拓苒药物科学研究有限公司 | 2023-03-10 | — | — | CN | disclosed |
| CN-109928964-B | Synthetic method of axitinib intermediate | 江苏开元药业有限公司 | 2022-04-15 | — | — | CN | disclosed |
| US-20220002287-A1 | INDAZOLE KINASE INHIBITOR AND USE THEREOF | Tarapeutics Science Inc. (CN) | 2022-01-06 | — | — | US | disclosed |
| CN-113350347-A | Novel use of indazole compound | 安徽中科拓苒药物科学研究有限公司 | 2021-09-07 | — | — | CN | disclosed |
| CN-112442009-A | Deuterated compounds and their use for treating cancer | 润佳（苏州）医药科技有限公司 | 2021-03-05 | — | — | CN | disclosed |
| US-9580406-B2 | Processes for the preparation of axitinib | SIGNA S.A. DE C.V. (MX) | 2017-02-28 | — | — | US | disclosed |
| US-20160318898-A1 | Processes for the Preparation of Axitinib | SIGNA S.A. DE C.V. (MX) | 2016-11-03 | — | — | US | disclosed |
| US-20160318898-A1 | Processes for the Preparation of Axitinib | SIGNA S.A. DE C.V. (MX) | 2016-11-03 | — | — | US | disclosed |
| US-20160318898-A1 | Processes for the Preparation of Axitinib | SIGNA S.A. DE C.V. (MX) | 2016-11-03 | — | — | US | disclosed |
| WO-2009036066-A1 | VEGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | CURIS, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | CURIS, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | CURIS, INC. | 2008-09-11 | — | — | US | disclosed |
| WO-2008033747-A9 | MULTI-FUNCTIONAL SMALL MOLECULES AS ANTI-PROLIFERATIVE AGENTS | CURIS INC (MA) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008033747-A2 | MULTI-FUNCTIONAL SMALL MOLECULES AS ANTI-PROLIFERATIVE AGENTS | CURIS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | HDAC1, HDAC6, HDAC5 | CYP4F2 4589/4885CYP4A11 4660/4885RET 2991/4885 |
| US-12162876-B2 | Indazole kinase inhibitor and use thereof | FLT3, PDGFRB, FLT1 | CYP4F2 1658/4885CYP4A11 892/4885RET 29/4885 |
| US-20220002287-A1 | INDAZOLE KINASE INHIBITOR AND USE THEREOF | FLT3, FGFR1, FLT1 | CYP4F2 1580/4885CYP4A11 758/4885RET 65/4885 |
| US-20160318898-A1 | Processes for the Preparation of Axitinib | AURKA, AURKC, AURKB | CYP4F2 1931/4885CYP4A11 1089/4885RET 356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.